AIM:To study the potential role of dependence statuson CB_(1)-mediated blockade of ethanol self-administra-tion.METHODS:We examined the effects of thecannabinoid antagonist SR141716A(0,0.03,0.3,and 3 mg/kg)on pperant ...AIM:To study the potential role of dependence statuson CB_(1)-mediated blockade of ethanol self-administra-tion.METHODS:We examined the effects of thecannabinoid antagonist SR141716A(0,0.03,0.3,and 3 mg/kg)on pperant ethanol(10%v/v)self-administration in male Wistar rats that were madeethanol-dependent by chronic(14 d)exposure toethanol vapor-chambers or exposed to air in identicalvapor chambers.RESULTS:Dependent animalsresponded more for ethanol than did air controlnondependent tats.The acute administration of a 3mg/kg dose of SR141716A almost suppressed ethanolself-administration ouly in ethanol dependent animals.However,operant responses for food were not afected by the administration of SR141716A.CONCLU.SION:These results further support that cannabinoid CB_(1) receptor blockade may have a potential utility for the treatment of alcobolism.展开更多
Portal hypertension is most frequently associated with cirrhosis and is a major driver for associated complications,such as variceal bleeding,ascites or hepatic encephalopathy.As such,clinically significant portal hyp...Portal hypertension is most frequently associated with cirrhosis and is a major driver for associated complications,such as variceal bleeding,ascites or hepatic encephalopathy.As such,clinically significant portal hypertension forms the prelude to decompensation and impacts significantly on the prognosis of patients with liver cirrhosis.At present,non-selective bblockers,vasopressin analogues and somatostatin analogues are the mainstay of treatment but these strategies are far from satisfactory and only target splanchnic hyperemia.In contrast,safe and reliable strategies to reduce the increased intrahepatic resistance in cirrhotic patients still represent a pending issue.In recent years,several preclinical and clinical trials have focused on this latter component and other therapeutic avenues.In this review,we highlight novel data in this context and address potentially interesting therapeutic options for the future.展开更多
基金DGICYT PM 96/0047,Comunidad de Madrid and Plan Nacional Sobre Drogas(MN,FRF)National Institutes of Health grants AA 06420AA 08459 from the National Institute on Alcohol Abuse and Alcoholism(GFK and AJR)
文摘AIM:To study the potential role of dependence statuson CB_(1)-mediated blockade of ethanol self-administra-tion.METHODS:We examined the effects of thecannabinoid antagonist SR141716A(0,0.03,0.3,and 3 mg/kg)on pperant ethanol(10%v/v)self-administration in male Wistar rats that were madeethanol-dependent by chronic(14 d)exposure toethanol vapor-chambers or exposed to air in identicalvapor chambers.RESULTS:Dependent animalsresponded more for ethanol than did air controlnondependent tats.The acute administration of a 3mg/kg dose of SR141716A almost suppressed ethanolself-administration ouly in ethanol dependent animals.However,operant responses for food were not afected by the administration of SR141716A.CONCLU.SION:These results further support that cannabinoid CB_(1) receptor blockade may have a potential utility for the treatment of alcobolism.
文摘Portal hypertension is most frequently associated with cirrhosis and is a major driver for associated complications,such as variceal bleeding,ascites or hepatic encephalopathy.As such,clinically significant portal hypertension forms the prelude to decompensation and impacts significantly on the prognosis of patients with liver cirrhosis.At present,non-selective bblockers,vasopressin analogues and somatostatin analogues are the mainstay of treatment but these strategies are far from satisfactory and only target splanchnic hyperemia.In contrast,safe and reliable strategies to reduce the increased intrahepatic resistance in cirrhotic patients still represent a pending issue.In recent years,several preclinical and clinical trials have focused on this latter component and other therapeutic avenues.In this review,we highlight novel data in this context and address potentially interesting therapeutic options for the future.
